Regenosine logo — Harnessing the healing potential of adenosine for tissue reg...

Regenosine

Harnessing the healing potential of adenosine for tissue regeneration

Founded 2018 United States Jersey City, United States 2 employees Grant Total: $1.84M Biotechnology, Health Care +1

General Information

Company Name Regenosine
Founded Year 2018
Location United States Jersey City, United States +1
Employees 2
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

Get notified when Regenosine moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Regenosine

Regenosine is a privately held biotechnology startup founded in 2018, with a vision to revolutionize the treatment of osteoarthritis by leveraging the healing potential of adenosine for tissue regeneration. Their proprietary platform technology focuses on developing and marketing first-in-class regenerative therapies, with a lead product aimed at regenerating cartilage in joints affected by osteoarthritis. Their innovative approach targets the rapidly growing joint preservation market, offering a disease-modifying therapy with uncompromising efficacy relative to existing technologies. This breakthrough has the potential to significantly improve clinical outcomes, enhance patient quality of life, and reduce the overall healthcare costs associated with regenerative medicine. Their most recent investment of $25.00K came in the form of a grant from NJEDA on 16 February 2023. Regenosine operates from the United States, and their emphasis on pioneering regenerative therapies positions them as a promising player within the biotechnology, healthcare, and pharmaceutical industries.

Taxonomy: regenerative medicine, osteoarthritis, cartilage regeneration, purinergic system, joint preservation, disease modifying therapy, clinical outcomes, proprietary technology, regenerative therapies, healthcare delivery, patient quality of life

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
16 Feb 2023
Grant •••••• 1
Investor
02 Aug 2022
Grant •••••• 1
Investor
01 Oct 2021
Seed Round •••••• 1
Investor
01 Jan 2020
Pre Seed Round •••••• 1
Investor
12 Jun 2019

Regenosine Alternatives & Competitors

Regenosine vs

Advancing regenerative medicine with innovative cell sheet therapies for eyes, esophagus, heart, gum...

Post Ipo Equity
Health Care, Marketing
Regenosine vs
Remedium Bio
Remedium Bio United States

We believe that any disease can be cured

Grant
17 employees
Biotechnology, Health Care
Regenosine vs
Amplicore Inc.
Amplicore Inc. United States

At Amplicore, we develop injectable therapeutics to serve unmet medical needs in musculoskeletal dis...

Seed
7 employees
Biotechnology, Health Care

FAQ About Regenosine

Harnessing the healing potential of adenosine for tissue regeneration
Regenosine was founded in 2018.
Regenosine is headquartered in Jersey City, United States.
Regenosine operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Regenosine has approximately 2 employees.
Regenosine has completed 5 funding rounds, raising a total of $1.84M. The latest funding stage is Grant.
Top alternatives and competitors to Regenosine include CellSeed, Remedium Bio, Amplicore Inc., CIMed Healthcare Sdn Bhd, Stem Cell Cure India. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Regenosine and CellSeed are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Regenosine and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy